Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY CROW

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1164425211
CMS profile
279622
Location
KINGWOOD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,993.52

206 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,885.73 204
Education $107.79 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY CROW

NPI 1164425211 · CMS profile ID 279622

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

KINGWOOD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164425211?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY CROW, NPI 1164425211, CMS profile ID 279622. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164425211?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MARY CROW, NPI 1164425211, CMS profile ID 279622. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164425211?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MARY CROW, NPI 1164425211, CMS profile ID 279622, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 206 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1164425211?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

206 matching records · $3,993.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 206 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 206.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharming Healthcare, Inc. $21.3909/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029328401 CMS
E.R. Squibb & Sons, L.L.C. $16.9609/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015974093 CMS
Eisai Inc. $19.1509/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023321985 CMS
AbbVie Inc. $24.3309/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996549829 CMS
PFIZER INC. $18.3909/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049795611 CMS
Takeda Pharmaceuticals U.S.A., Inc. $38.7908/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055373379 CMS
Lilly USA, LLC $16.2208/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031863925 CMS
TAIHO ONCOLOGY, INC. $23.5608/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055231325 CMS
Novartis Pharmaceuticals Corporation $11.1308/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991610305 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5108/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996847679 CMS
Novartis Pharmaceuticals Corporation $8.8308/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991610301 CMS
E.R. Squibb & Sons, L.L.C. $13.9108/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015974065 CMS
AVEO Pharmaceuticals, Inc. $21.6108/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049062417 CMS
Genentech USA, Inc. $25.1108/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040455733 CMS
E.R. Squibb & Sons, L.L.C. $16.3108/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015974061 CMS
Amgen Inc. $15.6108/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020017317 CMS
BeiGene USA, Inc. $22.3908/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051183087 CMS
AbbVie Inc. $3.3108/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996549825 CMS
Eisai Inc. $16.7908/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023321981 CMS
Merck Sharp & Dohme LLC $23.6908/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048409317 CMS
Novartis Pharmaceuticals Corporation $17.0408/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991610297 CMS
Amgen Inc. $15.4508/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020017311 CMS
PFIZER INC. $10.5108/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050087039 CMS
Regeneron Healthcare Solutions, Inc. $20.9408/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999136977 CMS
Incyte Corporation $18.2408/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044429405 CMS
AbbVie Inc. $3.5007/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996549821 CMS
Eisai Inc. $19.9307/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023321983 CMS
GlaxoSmithKline, LLC. $9.1407/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003337889 CMS
Mirati Therapeutics, Inc. $18.0607/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057988831 CMS
Amgen Inc. $14.9707/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020017315 CMS
Astellas Pharma US Inc $16.0607/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034314805 CMS
AbbVie Inc. $3.1207/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996549817 CMS
Celgene Corporation $16.4807/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015974009 CMS
AVEO Pharmaceuticals, Inc. $21.1507/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049062423 CMS
PFIZER INC. $18.7907/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049868987 CMS
Novartis Pharmaceuticals Corporation $2.1507/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991610289 CMS
Novartis Pharmaceuticals Corporation $21.8307/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991610293 CMS
Genentech USA, Inc. $13.1207/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040455709 CMS
GlaxoSmithKline, LLC. $26.3107/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003337881 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.2207/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996847681 CMS
CTI BioPharma Corp. $21.9807/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039693439 CMS
Novartis Pharmaceuticals Corporation $13.1607/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991610283 CMS
Ipsen Biopharmaceuticals, Inc $13.0707/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045443977 CMS
PFIZER INC. $2.0007/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049910571 CMS
PFIZER INC. $32.2206/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049954399 CMS
Janssen Biotech, Inc. $27.2806/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988415091 CMS
Puma Biotechnology, Inc. $19.2506/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059048905 CMS
Seagen Inc. $15.6106/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995723279 CMS
TAIHO ONCOLOGY, INC. $20.9206/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055227411 CMS
AbbVie Inc. $4.2606/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996549813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,872.74 234
PY2020 $3,234.04 172
PY2021 $3,747.67 193
PY2022 $3,106.89 171
PY2023 $3,993.52 206
PY2024 $276.76 8
PY2025 $279.75 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $633,304.43 15
PY2024 Principal investigator $276,373.86 17
PY2023 Principal investigator $91,909.48 32
PY2022 Principal investigator $302,873.61 33
PY2021 Principal investigator $2,021,834.63 136
PY2020 Principal investigator $2,043,067.45 246
PY2019 Recipient $167.14 1
PY2019 Principal investigator $1,112,253.42 216

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,500.00 12/29/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL CONSULTANTS LLC
Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression No dispute reported 06/30/2026 1184280368
Principal investigator 1 National Marrow Donor Program $7,000.00 11/07/2025 Non-covered Recipient Entity
Renovatio Clinical Consultants
A Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistimab Alone versus Lenalidomide Alone in Participants with newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4, EMN30) No dispute reported 06/30/2026 1249325331
Principal investigator 1 National Marrow Donor Program $7,000.00 11/07/2025 Non-covered Recipient Entity
Renovatio Clinical Consultants
A Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistimab Alone versus Lenalidomide Alone in Participants with newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4, EMN30) No dispute reported 06/30/2026 1249325333
Principal investigator 1 Genentech, Inc. $2,671.90 10/28/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC No dispute reported 06/30/2026 1211642298
Principal investigator 1 Genentech, Inc. $1,500.00 10/02/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
A PHASE 1B EVALUATING SAFETY, EFFICACY, PK AND PD OF GLOFITAMAB PLUS GEM-OX IN REM PTSWITH R/R DLBCL No dispute reported 06/30/2026 1211642381
Principal investigator 1 Organon Llc $150.00 09/19/2025 Non-covered Recipient Entity
Renovatio clinical
7339-008 No dispute reported 06/30/2026 1173042108
Principal investigator 1 Genentech, Inc. $54,513.00 08/08/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1211642412
Principal investigator 1 PFIZER INC. $43,484.00 07/14/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL CONSULTANTS INC
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228822722
Principal investigator 1 Amgen Inc. $99,000.00 04/24/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL CONSULTANTS LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy No dispute reported 06/30/2026 1246647144
Principal investigator 1 Genentech, Inc. $500.00 03/20/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len No dispute reported 06/30/2026 1211642330
Principal investigator 1 Janssen Research & Development, LLC $74,750.00 02/24/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175377837
Principal investigator 1 Amgen Inc. $189,294.53 01/27/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy No dispute reported 06/30/2026 1246647148
Principal investigator 1 Genentech, Inc. $39,411.00 01/21/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC No dispute reported 06/30/2026 1211642291
Principal investigator 1 Genentech, Inc. $50,765.00 01/21/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC No dispute reported 06/30/2026 1211642295
Principal investigator 1 Genentech, Inc. $50,765.00 01/21/2025 Non-covered Recipient Entity
RENOVATIO CLINICAL
A PHASE 1B EVALUATING SAFETY, EFFICACY, PK AND PD OF GLOFITAMAB PLUS GEM-OX IN REM PTSWITH R/R DLBCL No dispute reported 06/30/2026 1211642319